Skip to main content
. 2012 May 14;11:32. doi: 10.1186/1476-4598-11-32

Figure 3.

Figure 3

Galectin-1 immunohistochemistry confirms preferential expression at the invasive edge of the glioblastoma xenograft.(A) IgG control antibody (B) Galectin-1 staining (C) A human-specific vimentin antibody identifies all human cells in the field.